KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Travere Therapeutics (TVTX) over the last 13 years, with Q2 2025 value amounting to $2.1.

  • Travere Therapeutics' Debt to Equity changed N/A to $2.1 in Q2 2025 from the same period last year, while for Jun 2025 it was $2.1, marking a year-over-year change of. This contributed to the annual value of $1.16 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Travere Therapeutics reported Debt to Equity of $2.1 as of Q2 2025.
  • In the past 5 years, Travere Therapeutics' Debt to Equity ranged from a high of $2.1 in Q2 2025 and a low of -$2.25 during Q3 2024
  • Over the past 5 years, Travere Therapeutics' median Debt to Equity value was $0.06 (recorded in 2023), while the average stood at $0.32.
  • Per our database at Business Quant, Travere Therapeutics' Debt to Equity crashed by 7026.72% in 2021 and then surged by 56691.94% in 2022.
  • Quarter analysis of 5 years shows Travere Therapeutics' Debt to Equity stood at $0.02 in 2021, then soared by 566.92% to $0.16 in 2022, then tumbled by 63.74% to $0.06 in 2023, then skyrocketed by 1862.55% to $1.16 in 2024, then surged by 80.82% to $2.1 in 2025.
  • Its last three reported values are $2.1 in Q2 2025, $2.09 for Q1 2025, and $1.16 during Q4 2024.